Alpha 2.0
Login Register
» Authors » Hitoe Torisu-Itakura

Hitoe Torisu-Itakura

Explore the profile of Hitoe Torisu-Itakura including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 24
Citations 203
Followers 0
Related Specialties
Dermatology
General Medicine
General Surgery
Top 10 Co-Authors
Donald L Morton
Richard Essner
Norito Katoh
Mamitaro Ohtsuki
Akio Tanaka
Yoji Morisaki
Hidetoshi Takahashi
Yukari Okubo
Yoshitaka Isaka
Takashi Matsuo
Published In
Dermatol Ther (Heidelb)
Curr Med Res Opin
J Immunother
Acta Derm Venereol
J Dermatol
Affiliations
Soon will be listed here.
Recent Articles
1.
Safety and effectiveness of ixekizumab in Japanese patients with psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis: Post-marketing surveillance
Torii H, Morita A, Yamamoto C, Dong J, Tsujimoto M, Matsuo T, et al.
J Dermatol . 2025 Mar; PMID: 40079483
We report findings from a post-marketing study conducted from November 2016 to September 2022, which evaluated the safety and effectiveness of ixekizumab in Japanese patients with psoriasis under routine clinical...
2.
Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J)
Katoh N, Tanaka A, Takahashi H, Shimizu R, Kataoka Y, Torisu-Itakura H, et al.
Curr Med Res Opin . 2024 Dec; 41(1):1-12. PMID: 39625230
Objective: To evaluate efficacy and safety of lebrikizumab combined with topical corticosteroids (TCS) in Japanese patients with moderate-to-severe atopic dermatitis (AD). Methods: Phase 3, randomized, double-blind, placebo-controlled study (ADhere-J; NCT04760314)...
3.
Long-term management of moderate-to-severe atopic dermatitis with lebrikizumab and concomitant topical corticosteroids: a 68-week, randomized, double-blind, placebo-controlled phase III trial in Japan (ADhere-J)
Katoh N, Tanaka A, Takahashi H, Shimizu R, Kataoka Y, Torisu-Itakura H, et al.
Br J Dermatol . 2024 Oct; PMID: 39442013
Background: Moderate-to-severe atopic dermatitis (AD) impacts patients' quality of life (QOL). More treatment options are urgently needed to manage this chronic disease. Lebrikizumab is a monoclonal antibody that binds to...
4.
Lebrikizumab Combined with Topical Corticosteroids Improves Patient-reported Outcomes in Japanese Patients with Moderate-to-severe Atopic Dermatitis
Tanaka A, Igawa K, Takahashi H, Shimizu R, Kataoka Y, Torisu-Itakura H, et al.
Acta Derm Venereol . 2024 Sep; 104:adv34375. PMID: 39248292
Lebrikizumab has previously demonstrated efficacy in Phase 3 trials: ADvocate1 and ADvocate2 (as monotherapy), ADhere, and ADhere-J (in combination with topical corticosteroids). Here, the impact of lebrikizumab combined with low-...
5.
Patient and family burden in pediatric atopic dermatitis and its treatment pattern in Japan
Otsuka A, Wang C, Torisu-Itakura H, Matsuo T, Isaka Y, Anderson P, et al.
Int J Dermatol . 2024 May; 63(11):e322-e334. PMID: 38812086
Background: This study evaluated the level of burden in pediatric and adolescent atopic dermatitis (AD) patients in Japan, the associated burden on caregivers/families, and whether this burden varied with age....
6.
Treatment persistence of interleukin-17 inhibitor class drugs among patients with psoriasis in Japan: a retrospective database study
Wang C, Torisu-Itakura H, Hanada T, Matsuo T, Cai Z, Osaga S, et al.
J Dermatolog Treat . 2023 Jul; 34(1):2229465. PMID: 37403477
Background And Objective: Real-world evidence on persistence of interleukin-17 inhibitors (IL-17i) as a drug class among Japanese patients with psoriasis is lacking. Hence, we aimed to describe persistence rates of...
7.
Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials
Katoh N, Takita Y, Isaka Y, Nishikawa A, Torisu-Itakura H, Saeki H
Dermatol Ther (Heidelb) . 2022 Oct; 12(12):2765-2779. PMID: 36255569
Introduction: Baricitinib is an oral selective Janus kinase (JAK)1/JAK2 inhibitor approved in Japan and the European Union for the treatment of atopic dermatitis (AD). The aim of this study is...
8.
Impact of itch and skin pain on quality of life in adult patients with atopic dermatitis in Japan: results from a real-world, point-in-time, survey of physicians and patients
Torisu-Itakura H, Anderson P, Piercy J, Pike J, Sakamoto A, Kabashima K
Curr Med Res Opin . 2022 Jul; 38(8):1401-1410. PMID: 35787197
Objective: Itch is a common symptom of atopic dermatitis (AD), however, there is limited evidence of the frequency and association of skin pain alongside itch. This study assessed the incremental...
9.
Ixekizumab 80 mg Every 2 Weeks Treatment Beyond Week 12 for Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis
Morita A, Okubo Y, Morisaki Y, Torisu-Itakura H, Umezawa Y
Dermatol Ther (Heidelb) . 2021 Dec; 12(2):481-494. PMID: 34967916
Introduction: In 2018, ixekizumab (80 mg every 2 weeks [Q2W] beyond Week 12) received approval in Japan for patients with generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP). This open-label...
10.
Comparison of Treatment Goals between Users of Biological and Non-Biological Therapies for Treatment of Psoriasis in Japan
Okubo Y, Tang A, Inoue S, Torisu-Itakura H, Ohtsuki M
J Clin Med . 2021 Dec; 10(24). PMID: 34945027
Background: Previously, our cross-sectional observational study in Japan revealed high (68%) discordance within treatment goals between psoriasis patients and their physicians. Objective: This secondary analysis aimed to determine whether patient...